Preparations of recombinant follicle-stimulating hormone (FSH) alfa and delta induce different intracellular signals in vitro

Recombinant follicle-stimulating hormone (FSH)-based drugs Rekovelle® and Gonal-F® are produced in different host cell lines, i.e. the genetically modified human fetal retinal cell line (PER.C6®) and Chinese hamster ovary (CHO), respectively. Source cells lead to hormone preparations with distinct glycosylation profiles, possibly impacting the pattern of hormone-mediated intracellular signaling cascades. In this study, we compared the preparation-specific intracellular signalling pattern and receptor internalization in vitro. In transfected HEK293 cells expressing the FSH receptor (FSHR), we found that Rekovelle® is more potent than Gonal-F® in activating dose-dependent intracellular cAMP and CRE promoter activity, as an issue detectable in the nM concentrations range. Interestingly, Rekovelle® had a biphasic behaviour on the cAMP-pathway, since the 1 μM drug concentration (33.3 μg/ml) leads to inhibition of cAMP and CRE response, which did not occur with the equimolar Gonal-F® concentration. This event was accompanied by recruitment of β-arrestin 2 and FSHR routing to the late endosomes. To evaluate whether cAMP and CRE inhibition by 1 μM Rekovelle® depends on FSHR internalization, FSH dose-response experiments were performed in β-arrestin 2 knockout HEK293 cell line, where 1 μM Rekovelle® resulted in an intracellular cAMP increase. In conclusion, we found the mechanism underlying different modes of action between follitropin alfa and delta, as an issue likely linked to different glycan profiles, supporting the rationale for a tailored clinical use of these drugs.

Authors

Institutions

Publication Details

Journal
Molecular and Cellular Endocrinology
Published
2026-11-16
DOI
https://doi.org/10.1016/j.mce.2026.112950
Primary Topic
Receptor Mechanisms and Signaling
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preparations of recombinant follicle-stimulating hormone (FSH) alfa and delta induce different intracellular signals in vitro

Livio Casarini, Lara Baschieri, Samantha Sperduti, Clara Lazzaretti et al.
1 links
Molecular and Cellular Endocrinology
Receptor Mechanisms and Signaling
article

Preparations of recombinant follicle-stimulating hormone (FSH) alfa and delta induce different intracellular signals in vitro

Livio Casarini, Lara Baschieri, Samantha Sperduti, Clara Lazzaretti, Carmela Perri, Elisa Mascolo, Giada Mercanile, Claudia Fusco, Manuela Simoni
article en

Abstract

Recombinant follicle-stimulating hormone (FSH)-based drugs Rekovelle® and Gonal-F® are produced in different host cell lines, i.e. the genetically modified human fetal retinal cell line (PER.C6®) and Chinese hamster ovary (CHO), respectively. Source cells lead to hormone preparations with distinct glycosylation profiles, possibly impacting the pattern of hormone-mediated intracellular signaling cascades. In this study, we compared the preparation-specific intracellular signalling pattern and receptor internalization in vitro. In transfected HEK293 cells expressing the FSH receptor (FSHR), we found that Rekovelle® is more potent than Gonal-F® in activating dose-dependent intracellular cAMP and CRE promoter activity, as an issue detectable in the nM concentrations range. Interestingly, Rekovelle® had a biphasic behaviour on the cAMP-pathway, since the 1 μM drug concentration (33.3 μg/ml) leads to inhibition of cAMP and CRE response, which did not occur with the equimolar Gonal-F® concentration. This event was accompanied by recruitment of β-arrestin 2 and FSHR routing to the late endosomes. To evaluate whether cAMP and CRE inhibition by 1 μM Rekovelle® depends on FSHR internalization, FSH dose-response experiments were performed in β-arrestin 2 knockout HEK293 cell line, where 1 μM Rekovelle® resulted in an intracellular cAMP increase. In conclusion, we found the mechanism underlying different modes of action between follitropin alfa and delta, as an issue likely linked to different glycan profiles, supporting the rationale for a tailored clinical use of these drugs.

Molecular and Cellular EndocrinologyVol. 624
University of Modena and Reggio Emilia (IT), Azienda Ospedaliero-Universitaria di Modena (IT)
Ferring Pharmaceuticals, Ministero dell'Istruzione e del Merito
Good health and well-being
Receptor Mechanisms and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon